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Endosomal-trafﬁckingParkinson's disease is a neurodegenerative disorder, characterized by accumulation and misfolding of
α-synuclein. Although the level of α-synuclein in neurons is fundamentally linked to the onset of neurodegen-
eration, multiple pathways have been implicated in its degradation, and it remains unclear which are the critical
ubiquitination enzymes that protect against α-synuclein accumulation in vivo. The ubiquitin ligase Nedd4 tar-
gets α-synuclein to the endosomal–lysosomal pathway in cultured cells. Here we asked whether Nedd4-
mediated degradation protects against α-synuclein-induced toxicity in the Drosophila and rodent models of
Parkinson's disease. We show that overexpression of Nedd4 can rescue the degenerative phenotype from
ectopic expression ofα-synuclein in theDrosophila eye. Overexpressed Nedd4 in theDrosophila brain prevented
the α-synuclein-induced locomotor defect whereas reduction in endogenous Nedd4 by RNAi led to worsening
motor function and increased loss of dopaminergic neurons. Accordingly, AAV-mediated expression of wild-
type but not the catalytically inactive Nedd4 decreased the α-synuclein-induced dopaminergic cell loss in the
rat substantia nigra and reduced α-synuclein accumulation. Collectively, our data in two evolutionarily distant
model organisms strongly suggest that Nedd4 is a modiﬁer of α-synuclein pathobiology and thus a potential
target for neuroprotective therapies.
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY license. Introduction
Parkinson's disease (PD) is a common, age-related neurodegenera-
tive disorder without cure. Although primarily a movement disorder,
the disease process is eventually widespread causing dementia
and other non-motor symptoms. This relentless clinical course is ac-
companied by neuronal loss and intracellular accumulation of
misfolded α-synuclein in the dopaminergic neurons of the substantia
nigra (SN) and other brain regions (Tofaris and Spillantini, 2007). Treat-
ments that aim to slow down or stop neurodegeneration in PD are lack-
ing. There is now extensive evidence indicating that α-synuclein
content in neurons is critical for the onset of neurodegeneration; familial
cases with α-synuclein gene multiplications show a strong gene-dosagecal Neurosciences, University of
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ct.com).
.Open access under CC BY license. effect (Ross et al., 2008) and α-synuclein promoter polymorphisms that
increase protein expression are a risk factor for PD (Maraganore et al.,
2006). In animal studies, overexpression of human α-synuclein leads
to degeneration of nerve terminals and locomotor defects (Tofaris
et al., 2006; Chung et al., 2009a, 2009b) and such changes can be re-
versed when the transgene is switched off (Lim et al., 2011). Conversely,
knockout of α-synuclein in mice confers protection against certain
toxins (Dauer et al., 2002). Therefore, promoting the degradation of
α-synuclein and thus reducing its basal level inside neurons could
represent a novel neuroprotective strategy for PD. Such strategy neces-
sitates the identiﬁcation of enzymes that directly catalyze the clearance
of α-synuclein and demonstration that boosting their activity is neuro-
protective in animalmodels. Proteins destined for selective degradation
are conjugated to a ubiquitin chain in a three-step catalytic process
which involves a ubiquitin-activating enzyme E1, a ubiquitin conjugat-
ing enzyme E2 and a ubiquitin ligase (E3). There aremore than 650 E3s,
which regulate substrate speciﬁcity and different types of ubiquitin
linkages, which determine whether the protein is degraded by the pro-
teasome or the lysosome. Although both proteasomes and lysosomes
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important in PD pathogenesis (Tofaris, 2012). We have previously
shown that Nedd4 (neuronally-expressed developmentally down-
regulated gene 4) is a ubiquitin ligase for α-synuclein (Tofaris et al.,
2011). Since Nedd4 targets substrates to lysosomal degradation, we hy-
pothesized that it is protective against α-synuclein toxicity in relevant
animal models of PD.
Materials and methods
Drosophila genotypes
The UAS-α-synucleinwas obtained from M. Feany (Harvard Medical
School) and the UAS-dNedd4 line was obtained from M. Baron
(Manchester University). UAS-dNedd4-RNAi 13121 was obtained from
the Vienna Drosophila RNAi Center. The GAL4 UAS expression
system was used to overexpress these transgenes either pan-
neuronally at 25 °C using an Elav-GAL4 driver, or speciﬁcally in the
eye using GMR-GAL4 at 25 and 28 °C. Driver lines were crossed to
w1118 to generate heterozygous controls. The following genotypes
were used: (1) Elav-GAL4/+; (2) Elav-GAL4/+; UAS-α-synuclein/+;
(3) Elav-GAL4/+; UAS-Nedd4 RNAi 13121/+; (4) Elav-GAL4/+; UAS-
dNedd4/+; (5) Elav-GAL4/+; UAS-α-synuclein/+; UAS-Nedd4 RNAi
13121/+; (6) Elav-GAL4/+; UAS-α-synuclein/+; UAS-dNedd4/+; (7)
GMR-GAL4/+; (8) UAS-α-synuclein/+; GMR-GAL4/+; (9) UAS-Nedd4
RNAi 13121/GMR-GAL4; (10) UAS-dNedd4/GMR-GAL4; (11) UAS-α-sy-
nuclein/+; UAS-Nedd4 RNAi 13121/GMR-GAL4; (12) UAS-α-synuclein/+;
UAS-dNedd4/GMR-GAL4. Flip-out mitotic clones were generated
using the inducible GAL4 driver, HsFlp, UAS-GFPnls; UAS-Dcr2;
tubNGAL80NGAL4/SM5, Cyo-TM6, Tb. The NGAL80N cassette is
recombined out following heat-shock, thereby inducing tub-GAL4 driven
expressionof genes under the control of theUASpromoter. The lines gen-
erated were: (1) HsFlp, UAS-GFPnls/+; UAS-α-synuclein/UAS-Dcr2;
tubNGAL80NGAL4/+; (2) HsFlp, UAS-GFPnls/+; UAS-Dcr2/+; tubN
GAL80NGAL4/UAS-Nedd4-RNAi; and (3) HsFlp, UAS-GFPnls/+; UAS-
Dcr2/+; tubNGAL80NGAL4/UAS-dNedd4. These progeny were heat-
shocked for 1 h at 37 °C at 24 h and 48 h after egg deposition.
Scanning electron microscopy of the Drosophila eye
Age-matched,maleﬂieswereﬁxed in 70% ethanol. Theﬂieswere then
dehydrated in 100% ethanol, dried and mounted on SEM stubs. The sam-
ples were then sputter coated with gold and imaged using a JEOL JSM
6390 scanning electron microscope. To quantitate the eye phenotype,
we randomly selected 20 ﬂies per genotype, which were scored by two
blinded assessors independently using objective features of severity that
were adapted from Pandey et al. (2007). Eyes were examined for abnor-
mal bristle orientation, ommatidial fusion or pitting and disorganization
of the ommatidial array, and given one point if this feature was present,
2 points if the affected area involvedmore than 5% of the eye and 4 points
if the affected area involved more than 25% of the eye.
Immunoﬂuorescence and confocal microscopy for Drosophila eyes
Larval eye discs were ﬁxed for 10 min in 4% paraformaldehyde.
Primary antibodies used were: mouse anti-α-synuclein (BD Transduc-
tion, 1:500) and rabbit anti-Nedd4 (Abcam, 1:500). The Cy5 conjugated
(Jackson ImmunoResearch, 1:1000) secondary antibodywas used. Sam-
ples were imaged using a Zeiss LSM 510 META confocal microscope.
Immunoblotting of Drosophila brain lysates
For each genotype 5male adult headswere homogenized in lysis buff-
er (150 mMNaCl, 10 mMTris pH7.4, 1% Triton-X, 0.1% SDS and complete
protease inhibitor cocktail, SIGMA). Samples were quantiﬁed and loaded
on a NuPAGE 10–12% Bis–Tris gel (Invitrogen). The following primaryantibodieswere:mouse anti-tubulin (Developmental Studies Hybridoma
Bank, 1:1000), mouse anti-α-synuclein, Syn1 (BD Transduction, 1:400),
rabbit anti-Nedd4 (Abcam, 1:5000), and rabbit anti-actin (Sigma,
1:1000). Blots were visualized using HRP-conjugated secondary antibod-
ies and the ECL Detection Reagent (Amersham).
Climbing assays
Locomotor function was assayed using a startle-induced negative
geotaxis assay and the climbing ability of the ﬂies measured under red
light (adapted from Feany and Bender, 2000). Up to 10 ﬂies were placed
per vial and tapped 3 times. For each line between 3 and 5 vials were in-
cluded in each experiment. The number of ﬂies above a predetermined
linewas recorded after 4 s of climbing. All lines were crossed andmain-
tained at 25 °C with a 12 h light/dark cycle. Similar results were obtain-
ed from two independently derived transgenic lines.
Viability assays
40 male ﬂies of each genotype were incubated at 25 °C in vials con-
taining standard media. Each day Drosophila were transferred to fresh
vials, and the number of ﬂies which had died was recorded. At the end
of the experiment, the remaining ﬂies were counted.
AAV2 nigral injections in rats
The AAV2/2-A53T α-synuclein and green ﬂuorescent protein (GFP)
vectors were prepared as previously described (Chung et al., 2009a,
2009b). The AAV2/2-Nedd4 vector consists of full-length rat wild-
type, or a Cys → Ser point mutation in the HECT domain catalytic
site. Both Nedd4WT and Nedd4C-S constructs were epitope-tagged
with T7 at the N-terminus and under the control of the human
synapsin promoter. The ﬁnal titer used for injection of the vectors was
2 × 1012 genome copies/ml. Animals were housed according to stan-
dard conditions, in a dark/light cycle of 12 h, with ad libitum access to
food andwater. Female Sprague–Dawley rats weighing ~250 g (Charles
River Laboratories) were used in the animal experiments and injected
as previously described (Chung et al., 2009a, 2009b). These experiments
had previously been approved by the McLean Hospital Institutional An-
imal Care and Use Committee. Stereotaxic coordinates for the surgeries
were taken from the “Rat Atlas” by Paxinos and Watson (1986). Before
surgery, the animals were anesthetized with xylazine and ketamine
(3 mg/kg and 60 mg/kg, respectively). The animals were placed in a
stereotaxic frame (Stoelting), where a 10 μl Hamilton syringe and 31
gauge needles were used as a delivery system. All injections were
made into the substantia nigra using the following anteroposterior
(AP), mediolateral (ML), and dorsoventral (DV) coordinates: ﬁrst site,
AP = −4.8 mm; ML = −2.0 mm; DV = −7.2 mm relative to dura,
second site, AP = −5.5 mm; ML = −1.9 mm, DV = 7.0 mm relative
to dura; toothbar (TB) set at −3.3 mm. For coinjection of AAV-A53T
α-synuclein with either AAV Nedd4WT or AAV Nedd4C-S, viruses
were mixed in the same infusate at a ﬁnal titer of 2 × 1012 genome
copies/ml. Two microliters of either A53T α-synuclein + AAV
Nedd4WT, A53T α-synuclein + AAV Nedd4C-S, or AAV GFP control
transgene was injected per site at a rate of 0.5 μl/min using
microinfusion pumps (Stoelting), with a wait time of 10 min between
injection. At 19 weeks post-AAV injection, animals were terminally
anesthetized and perfused as detailed in Chung et al. (2009a, 2009b).
Immunohistochemistry on rat brain sections
Immunohistochemistry was performed on serial free-ﬂoating
sections using the following primary antibodies: rabbit anti-tyrosine
hydroxylase (TH) (Pel Freez; 1:300), mouse anti-human α-synuclein
(LB509, Zymed, 1:500) and anti-goat T7 (AbCam, 1:200). Confocal
analysis was performed using a Zeiss LSK510/Meta station.
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Unbiased quantiﬁcation of TH/NeuN-positive neuronal numbers
within the SNc and ventral tegmental area (VTA) was performed by in-
vestigators blind to group treatments using a Zeiss Axiovert microscope
coupled to an Optronics Microﬁre digital camera for visualization of
tissue sections, and Stereo Investigator software, and using stereologic
principles as previously described (Chung et al., 2009a, 2009b). Brieﬂy,
TH/NeuN-positive neurons of the injected SN and VTA were counted
under brightﬁeld illumination at 40× magniﬁcation and the total num-
ber of TH/NeuN-positive neurons was estimated from coded slides
using the optical fractionator method. The anterior and posterior
boundaries of the SN included in the analysis were deﬁned according
to the area transduced by AAV2-GFP in preliminary experiments
[approximately−4.80 mm through−6.00 mm from bregma (accord-
ing to the rat brain atlas of Paxinos andWatson, 1986)]. The coefﬁcients
of error were calculated according to the procedure ofWest (1993) and
values b0.10 were accepted.
Biochemical fractionation of the rat brain tissue
Tissue was weighed and homogenized in 30 volumes of lysis buffer
(150 mM NaCl, 10 mM Tris pH7.4 and complete protease inhibitor
cocktail from SIGMA). All centrifugation steps were performed at 4 °C.
Homogenates were initially centrifuged at 1000 g for 5 min to remove
debris and nuclei and the resultant supernatants from this step were
centrifuged at 120,000 g for 30 min. The supernatant was designated
as the cytosolic fraction and the pellet was extracted in RIPA buffer
(150 mM NaCl, 10 mM Tris pH7.4, 1% Triton-X, 0.1% SDS and complete
protease inhibitor cocktail) and centrifuged at 120,000 g for 30 min.
The resulting pellet was solubilized in SDS and designated as
RIPA-insoluble/SDS soluble fraction.
Ubiquitination assay
Wild-type and A53T mutant human α-synuclein protein (untagged
full-length) was added in excess to the ubiquitination mixture contain-
ing 6His-E1 (50 nM), UbcH5 (750 nM), Nedd4 (500 nM) and ubiquitin
(59 mM) in a buffer composed of 20 mMTris–HCl (pH7.6), 20 mMKCl,
5 mMMgCl2, 2 mM ATP, and 1 mM DTT.
Statistics
For the climbing assay, the proportion of ﬂies which climbed above a
predetermined line were compared in order to account for different
numbers of ﬂies in some tubes caused by death or escape. Proportions
were ArcSin root transformed and a one-way ANOVA was performed
for each time point; when P b 0.05 a subsequent unplanned compari-
son using a Tukey–Kramer test was performed to determine which ge-
notypes signiﬁcantly differed from one another. For viability assays, log
rank tests were performed to individually compare each genotype to
elav-GAL4 controls, using a Bonferroni adjusted P-value (P = 0.0083)
to adjust for multiple comparisons.
Results
Nedd4 rescues the α-synuclein-induced rough eye phenotype
Nedd4 is a highly conserved E3 and essential for viability (Rotin and
Kumar, 2009). We therefore ﬁrst asked whether expression of wild-
type or catalytically inactive Nedd4 or knockdown of the endogenous
protein per se speciﬁcally in the Drosophila eye causes any phenotype.
We found that Nedd4 overexpression or knockdown did not cause a
phenotypewhereas expression of catalytically inactive nedd4was asso-
ciated with toxicity (Suppl. Fig. 1). Because of this ﬁnding, we asked
whether small changes in wild-type Nedd4 by overexpression orknockdown can modify the toxicity from ectopic expression of wild-
type human α-synuclein. In this model, transgenic expression of toxic
proteins causes cell degeneration, leading to a ‘rough eye’ phenotype
(Pandey et al., 2007) that depending on severity is detectable by light
or scanning electron microscopy (SEM). We used the GMR-GAL4 driver
and incubated the transgenic ﬂies at 25 °C and 28 °C to determine
whether slight variations in protein expression levels can induce a
phenotype. Using SEM, we found that at 28 °C, overexpression of
α-synuclein induced a rough eye phenotype (Fig. 1 panels A, B),
whereas concurrent over-production of Nedd4 (at 28 °C) rescued
this defect (Fig. 1D). Knockdown of endogenous Nedd4 using
transgenic expression of RNAi did not cause an obvious further
worsening of the α-synuclein-induced phenotype (Fig. 1C). Quanti-
ﬁcation of the phenotype severity is shown in Fig. 1K and detailed
in themethods. Nedd4 knockdownor overexpression byGMR-GAL4per
se did not cause an eye phenotype at 28 °C as detailed above. We con-
ﬁrmed the presence of α-synuclein, Nedd4 or Nedd4 RNAi transgenes
in the eye, by generating ﬂip-out clones in combination with immuno-
ﬂuorescence for α-synuclein or Nedd4 (Fig. 1 panels E–J).
Neuronal Nedd4 levels modify the motor phenotype in Drosophila express-
ing α-synuclein
Our ﬁndings in the Drosophila eye strongly argue that boosting
Nedd4 activity is required to mitigate the toxic phenotype from in-
creased ectopic expression ofα-synuclein. Although an indirectmecha-
nism of protection cannot be excluded, our previous in vitro ﬁndings
(Tofaris et al., 2011), suggest that at least in part, Nedd4-mediated
protection is due to enhanced degradation of α-synuclein in vivo. To
test this prediction, we expressed wild-type Nedd4 or its RNAi pan-
neuronally using the elav-GAL4driver.DrosophilaNedd4has two spliced
variants, a short isoform Nedd4S (~92 kDa), and a longer isoform
Nedd4L (~112 kDa) (Zhong et al., 2011). Both contain the C2 domain,
three WW domains which recognize proline-rich sequences on
protein-substrates and the catalytically active HECT domain. Previous
studies showed that ubiquitous expression of the short isoform does
not affect larval development and rescues the phenotype of Nedd4 mu-
tants in Drosophila, whereas overexpression of the long isoform causes
lethality (Zhong et al., 2011). We thus generated double transgenic
ﬂies co-expressing Nedd4 RNAi or the short isoform of Drosophila
Nedd4 with α-synuclein and measured the level of ectopically
expressed α-synuclein in total brain lysates in single and doubly
transgenic ﬂies. These experiments showed that when Nedd4 levels
were increased by 5–6 fold, a signiﬁcant 2-fold reduction in neuronal
α-synuclein was detected (Fig. 2A and Suppl. Fig. 2). To conﬁrm that
changes inα-synuclein protein levelswere not due to promoter compe-
tition or variable mRNA levels, we performed qPCR in these lines. These
data showed that α-synuclein mRNA is not signiﬁcantly different be-
tween transgenic lines andwere undetected in the elav-GAL4/+ control
ﬂies as expected (Fig. 2B). To test whether enhanced Nedd4-mediated
degradation of α-synuclein speciﬁcally in brain affords protection and
validate our earlier observations in the eye using an alternative read-
out of toxicity, we then measured the climbing ability of transgenic
ﬂies at different time-points after eclosion. This climbing response was
previously shown to reﬂect an age-related motor dysfunction due to
α-synuclein expression and thus a measure of α-synuclein-induced
toxicity (Chen et al., 2009; Feany and Bender, 2000). Strikingly, we
found that Nedd4 overexpression prevented the climbing deﬁcit that
is associated with α-synuclein expression (Fig. 3A) whereas Nedd4
knockdown signiﬁcantly worsened this climbing response in contrast
to the knockdown effect on the eye phenotype (Fig. 3B). Overexpression
or knockdown of Nedd4 per se did not alter the climbing ability when
compared to elav-GAL4 controls at the same (late) time points after
eclosion (Fig. 3C). In addition, we assessed lifespan and did not ﬁnd
any signiﬁcant difference in the transgenic lines that could account for
the difference in the climbing performance (Fig. 3D).
Fig. 1. Eye-speciﬁc expression of α-synuclein by GMR-GAL4 causes a rough eye phenotype that is prevented by Nedd4 co-expression. Unlike control ﬂies expressing GMR-GAL4/+ (A),
overexpression of α-synuclein caused a rough eye phenotype (B) that is detectable only by SEM. (C) The phenotype was not worsened in doubly transgenic ﬂies co-expressing Nedd4
RNAi and α-synuclein (labeled Syn/Nedd4 RNAi). (D) Overproduction of Nedd4 prevented the α-synuclein-induced degenerative eye phenotype (labeled Syn/Nedd4). Scale bar,
100 μm. ‘Flip-out’ clones conﬁrmed thatα-synuclein (E, F) Nedd4 (G, H) and Nedd4 RNAi (I, J) were readily expressed inGFP positive clones in larval eye discs upon heat shock. (K) Quan-
titative analysis of the severity of the eye phenotypes; n = 20 SEM images per group, p b 0.01 using ANOVA.
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ting, was not increased in brain lysateswhen Nedd4was knocked down
by 2-fold in neurons, the differential effect of Nedd4 RNAi in the motor
but not the eye phenotype, suggests that endogenous as opposed to
overexpressed Nedd4 may be critical for a subpopulation of neurons
that are especially vulnerable to α-synuclein toxicity. To address this
issue, we identiﬁed and counted the number of dopaminergic neurons
in the dorsomedial cluster, which were previously shown to be suscep-
tible to α-synuclein toxicity (Auluck et al., 2002; Feany and Bender,
2000). Our data showed that the combination of α-synuclein overex-
pression and Nedd4 knocked-down, led to a signiﬁcant reduction in
the number of TH-positive neurons in the dorsomedial cluster when
compared to controls, α-synuclein or Nedd4 RNAi expression
alone (Figs. 3E, F). In contrast, co-expression of Nedd4 prevented the
α-synuclein-induced dopaminergic cell loss (Figs. 3E, F). Thus, although
Nedd4 overexpression is generally protective against α-synuclein
toxicity, the endogenous protein is critical in vulnerable neuronal
subpopulations.
Overexpression of wild-type but not the catalytically inactive Nedd4
decreased dopaminergic cell loss in the rat model of α-synucleinopathy
To test the role of Nedd4 activity in dopaminergic neurons further
and assess the neuroprotective function of Nedd4 in a mammalian
animal model, we asked whether wild-type (Nedd4WT) or catalytically
inactive (active site cysteine mutated to serine, Nedd4C-S) Nedd4 ex-
pression prevents cell death from virally-mediated expression of the
human A53T mutant α-synuclein in dopaminergic neurons (Chung
et al., 2009a, 2009b). Co-expression of both Nedd4 and α-synuclein
was detected in the dopaminergic neurons (Fig. 4, panels A–E) and
levels of Nedd4 overexpression, as detected by immunoblotting, were
equal in the two lines (Figs. 4E and 5A). We have previously shown
that AAV-mediated overexpression of human A53T α-synuclein on
the synapsin promoter in rats produces a progressive degeneration of
SN pars compacta (SNc) dopaminergic neurons (Chung et al., 2009a,
2009b). Although the extent of cell loss in this model (32% loss
compared to GFP expressing values, Chung et al., 2009a, 2009b) is not
sufﬁcient to produce a clear behavioral phenotype or changes in striatal
nerve terminals, we used this system to speciﬁcally examine thenumber of SNc dopaminergic neurons at 19 weeks post-AAV co-
injection, a time-point in which there is signiﬁcant neurodegeneration.
Unbiased stereological quantiﬁcation of neurons co-labeled for NeuN
and TH showed that the number of nigral dopaminergic neurons in
rats injected with α-synuclein and Nedd4C-S was signiﬁcantly reduced
to 65.8% (±5.2) of GFP control values (p b 0.001). Importantly, the num-
ber of NeuN and TH doubly labeled neurons co-injected with α-
synuclein/Nedd4WT (84.2 ± 4.6% of GFP control) was signiﬁcantly in-
creased compared to the α-synuclein/Nedd4C-S group (p b 0.05) and
not signiﬁcantly different compared to GFP controls (p N 0.05) (Fig. 4,
panels F–I). These data suggest that the ubiquitin ligase activity of
Nedd4 is necessary to prevent α-synuclein-induced neurodegeneration
in vivo. In control experiments we did not ﬁnd signiﬁcant differences in
the extent of co-localization of either A53T α-synuclein and Nedd4WT,
or A53Tα-synuclein and Nedd4C-S (90.3 ± 3.2% and 94.8 ± 2.2% of neu-
rons respectively, p N 0.05). Triple co-localization of human α-synuclein,
T7 for tagged Nedd4 and TH within all remaining TH-immunoreactive
neurons in the SNc was 67 ± 10.6% for A53T α-synuclein + Nedd4WT
and 74.6 ± 6.4% for A53T α-synuclein + Nedd4C-S without a signiﬁcant
difference (p N 0.05, unpaired t-test) between the two animal groups.
Stereological analysis of neurons co-labeled with TH and NeuN in the
ventral tegmental area (Suppl Fig. 3), which is typically resistant to
AAV-mediated α-synuclein-induced neurodegeneration (Chung et al.,
2009a, 2009b), did not show a signiﬁcant difference between cell num-
bers. These data suggest that in the absence ofα-synuclein-induced cell
loss, expression of WT or catalytically inactive Nedd4 is not toxic to do-
paminergic neurons.
Nedd4-mediated degradation reduced the accumulation and aggregation
of α-synuclein in the SN
To assess whether Nedd4 protects by promoting the clearance of
α-synuclein in vivo, we performed serial fractionation and measured
the levels of cytosolic and RIPA-insoluble/SDS-soluble α-synuclein in
littermate animals. We found that the level of cytosolic α-synuclein
was reduced in Nedd4WT compared to Nedd4CS expressing animals,
whereas quantiﬁcation of the RIPA-insoluble/SDS-soluble fraction
showed signiﬁcantly increased gel-excluded and oligomeric forms of
α-synuclein (indicative of aggregated protein) in animals expressing
Fig. 2. Increased neuronal Nedd4 reduces α-synuclein levels in the Drosophila brain. (A) Representative immunoblot with three independent samples from each transgenic line: elav-
GAL4/+,α-synuclein ﬂies (Syn) and doubly transgenic α-synuclein ﬂies with either Nedd4 RNAi (labeled Syn/Nedd4 RNAi) or Nedd4 overexpression (labeled Syn/Nedd4). Quantitative
band densitometry showed that, relative to tubulin loading control, neuronal α-synuclein was signiﬁcantly reduced by 2-fold in ﬂies co-expressing Nedd4 (upper histogram). Neuronal ex-
pression of Nedd4was reduced by 2-fold in RNAi expressing ﬂies and increased by 5–6 fold in ﬂies expressing the short isoform of Nedd4 (lower histogram). Values representmean ± SEM
from three independent experiments. (B) Quantitative PCR did not showa signiﬁcant difference inα-synucleinmRNA levels between the three transgenic lines and no signalwas detected in
the control genotype as expected.
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aggregated forms were decreased when wild-type Nedd4 is
overexpressed. To determinewhether Nedd4 ubiquitinates monomeric
as well as aggregated forms of α-synuclein, we reconstituted the
ubiquitination ofwild-type andA53Tmutantα-synuclein in vitro as de-
scribed previously (Tofaris et al., 2011).We found that the A53Tmutant
α-synuclein is similarly ubiquitinated to the wild-type protein. Impor-
tantly, for the A53Tmutant, which is prone to aggregation, we observed
that aggregated species present in the reaction before the addition of
ubiquitin were also ubiquitinated as evidenced by the shift in their mo-
lecular weight following the addition of recombinant ubiquitin
(Fig. 5B). Collectively, these data suggest that Nedd4 overexpression
can prevent the accumulation of α-synuclein in vivo and may directly
promote the clearance of aggregated α-synuclein.
Discussion
We have provided multiple independent lines of evidence to show
that, the ubiquitin ligase Nedd4 protects against α-synuclein-inducedtoxicity in two animal models of PD. In Drosophila, we showed that
when Nedd4 activity is enhanced by overexpression, it is sufﬁcient to
prevent toxicity from high levels of ectopically expressed wild-type
human α-synuclein in the eye or the nervous system whereas endoge-
nous Nedd4 is especially critical for prevention of α-synuclein-induced
toxicity in the dopaminergic neurons. In the rat SN, using a complemen-
tary approach, we found that expression of wild-type but not inactive
Nedd4decreased degeneration of dopaminergic neurons that is induced
by chronic overexpression of A53T mutant human α-synuclein.
A role for Nedd4 in the human condition is supported by the identi-
ﬁcation of a coding SNP as a risk factor for idiopathic PD (Srinivasan
et al., 2009), the ﬁnding that Nedd4 mRNA expression is increased in
brain regions with Lewy body pathology (Dumitriu et al., 2012) and
our neuropathological observations that Nedd4 is up-regulated in a sub-
population of pigmented neurons containing Lewy bodies (Tofaris et al.,
2011). Since Nedd4 is a ubiquitin ligase that functions in the
endosomal–lysosomal pathway, our data are also consistent with
other studies which have implicated this pathway in PD pathogenesis
(Dodson et al., 2012) and genetic screens showing that genetic
Fig. 3. Nedd4 levels modify the α-synuclein-induced motor phenotype and dopaminergic cell number in Drosophila. (A) Accelerated loss of climbing ability was seen in transgenic ﬂies
expressingα-synuclein throughout the nervous system (elav-GAL4 driver). The climbing ability of doubly transgenic lines expressing Nedd4 andα-synuclein was signiﬁcantly improved
(shown by asterisks) when compared to α-synuclein expressing ﬂies and was similar to the control genotype, elav-GAL4/+. (B) Unlike the result in the eye, reduction of endogenous
Nedd4 speciﬁcally in the nervous system caused a worsening in the climbing scores, which were signiﬁcantly different between doubly transgenic Nedd4 RNAi/α-synuclein compared
to either α-synuclein or the control genotype, elav-GAL4/+ (error bars are hiddenwithin the symbols). (C) No signiﬁcant difference was detectedwhen Nedd4 per se was overexpressed
or knocked-down. *p b 0.05 using ANOVAwith subsequent Tukey–Kramer test. Values representmean ± SEM. (D) Kaplan–Meier survival curveswere similar at different days after eclo-
sion (DAE). (E) Dopaminergic neurons in the dorsomedial cluster were visualizedwith anti-TH antibodies and counted. (F) A signiﬁcant loss of dopaminergic neurons was seen in Nedd4
RNAi/α-synuclein doubly transgenic ﬂies when compared to α-synuclein or elav-GAL4/+ phenotypes. Co-expression of Nedd4 was protective against α-synuclein-induced cell loss
(n = 10 brains/group). *p b 0.05 using ANOVA with subsequent Tukey–Kramer test. Values represent mean ± SEM.
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relevant cell models (Willingham et al., 2003). A number of observa-
tions are consistent with the notion that degradation of α-synuclein
by lysosomes is an important pathway in PD pathogenesis: Mutations
in glucocerebrosidase (GBA), a lysosomal enzyme linked to Gaucher's
disease, are the most common genetic risk factor for sporadic PD
(Sidransky et al., 2009). In transgenic models, mutant GBA leads to
α-synuclein accumulation in ubiquitinated inclusions whereas virally-
mediated overexpression of wild-type GBA is protective (Sardiet al., 2011). Similarly, knockout of the lysosomal protease cathepsin
D in mice causes accumulation of α-synuclein in brain whereas
cathepsin D overexpression is protective (Cullen et al., 2009). In
this context, Nedd4, a ubiquitin ligase that targets proteins to lyso-
somes, provides an enzymatic link between this striking association
of α-synucleinopathy and lysosomal degradation, and given its spec-
iﬁcity for only a few protein-substrates, an opportunity for a targeted
therapy aimed at preventing the accumulation of α-synuclein in
brain. Although Nedd4 has other substrates, especially membrane-
Fig. 4. Overexpression of wild-type but not catalytically inactive Nedd4 preventsα-synuclein-induced loss of dopaminergic neurons. Virally-mediated overexpression of human A53T α-
synuclein at 19 weeks post-AAV injection was conﬁrmed using the LB509 antibody (panel A), and Nedd4 overexpression was veriﬁed using anti-T7 (panel B). TH was used to label do-
paminergic neurons (panel C). Co-expression of both Nedd4 and human α-synuclein within TH-immunoreactive SNc neurons is shown in panel D, and represents the boxed area illus-
trated in panel A. Examples of TH-immunoreactive neurons expressing both transgenes are marked with asterisks. Expression was also conﬁrmed by immunoblotting of SN lysates at
19 weeks with antibodies againstα-synuclein (Syn1) and T7 for Nedd4 (panel E). Representative images and highmagniﬁcation insets are shown in panels F–H for TH/NeuN doubly la-
beled neurons in the SNc for each group. (I) When compared to AAV-GFP controls (n = 5), there was a signiﬁcant reduction in the number of dopaminergic neurons in rats expressing
Nedd4C-S and A53Tα-synuclein (n = 8) whereas co-expression of Nedd4WT (n = 7) afforded protection. *p b 0.05, p b 0.001 (one-way ANOVA, Tukey's multiple comparison post-hoc
test). Scale bar, panels A, B = 200 μm, panel D = 50 μm, panels F–G = 100 μm, insets = 50 μm.
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evident from our observations on lifespan and those of others that
within a certain range of expression in the Drosophila nervous sys-
tem, Nedd4 levels per se do not cause defects in synaptogenesis or
axon guidance (Myat et al., 2009; Zhong et al., 2011).
Advancing age is the most important risk factor for developing spo-
radic PD. In our animal models age-related changes in either phenotype
or cell numbers due to α-synuclein expression were modiﬁed by
ubiquitin-dependent degradation by Nedd4. This ﬁnding raises the
more general possibility that with age the efﬁciency of protein
ubiquitination rather than degradation may be an important contribu-
tor to the development of PD and other neurodegenerative diseases.
One possible mechanism is oxidative inactivation of enzymes in the
ubiquitin pathway. In linewith this suggestion is theﬁnding that parkin,
another ubiquitin ligase implicated in autosomal-recessive PD, is oxida-
tively inactivated in sporadic forms of the disease (Lavoie et al., 2005).
Our data show that theubiquitin ligase activity of Nedd4 is necessary
for its neuroprotective action, which at least in part, is mediated by a
direct effect on α-synuclein levels. In Drosophila endogenous Nedd4
appears to have a tissue- and cell-speciﬁc protective effect: one
explanation is that although a 2-fold reduction in endogenous
Nedd4 is not sufﬁcient to further increase the levels of ectopically
overexpressed α-synuclein as assessed by immunoblotting of whole
brain lysates, the rate of α-synuclein clearance is altered in susceptible
cell populations in the living brain. The effect of Nedd4 overexpression
onα-synuclein levels in the ﬂy and rat brain tissue would be consistent
with such explanation. In addition, it is well established that α-
synuclein is degraded by multiple pathways (Tofaris et al., 2001, 2011;Webb et al., 2003) which may exhibit variable functional redundancy
in neuronal versus non-neuronal tissues. Alternatively, accumulation
of other cell-speciﬁc substrates could synergistically contribute to α-
synuclein-induced dysfunction as Nedd4 RNAi per se is not toxic. It is
also noteworthy that Nedd4 is up-regulated in surviving neurons
around areas of traumatic brain injury in mice (Sang et al., 2006) and
its yeast ortholog can protect against oxidative stress (Hoshikawa
et al., 2003) and was previously shown by us to protect against α-
synuclein toxicity in the corresponding yeast model (Tofaris et al.,
2011). Therefore, an additional,α-synuclein-independent protective ef-
fect cannot be excluded. This withstanding, our ﬁnding that Nedd4 is
protective against humanα-synuclein toxicity in two evolutionarily dis-
tantmodel organisms strongly suggests that activation of this conserved
ubiquitination pathway should be considered as a target for neuropro-
tective therapies. In striking conﬁrmation of this prediction, and while
our manuscript was under consideration, a genetic drug screen identi-
ﬁed a Nedd4 activator as a modiﬁer of α-synuclein toxicity in yeast
and iPSc-derived cortical neurons (Tardiff et al., 2013). Previous studies
showing that Nedd4 activity is regulated by intra-molecular interac-
tions (Wang et al., 2010) may also be informative in the development
of small molecule activators.
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